Buenos DIAs from Barcelona
The Drug Information Association hosted its 20th Annual European meeting in Barcelona, Spain, where industry experts discussed topics at the forefront of European pharma.
Drug Pooling: Power and Pitfalls
When done right, pooling clinical supplies can increase efficiency and contain costs, but limitations exist.
A Pandora's Box for Clinical Trials?
How one patient community on the Web is single-handedly forging new ground in the clinical trials world.
A Carrot and Sticks Approach
Award for excellence in human research protection is the incentive for better oversight and regulations.
Research, Investigator Conduct Under Scrutiny
Ketek probe raises questions about research oversight by FDA, sponsors, and investigators.
Global News
News tidbits from around the world
Marked Decline in Clinical Operations Productivity
A recent survey from KMR Group shows a 15% decline in clinical operations productivity since 2005.
Key Factors in CRO Selection
A recent survey uncovers key criteria that influence a sponsor's decision when selecting a CRO.
Animating Informed Consent
For the first time n a Phase 1 trial, 3D animation is used for informed consent.
EU Seeks Hematology Guidance
Europe aims to create new regulations regarding hematological malignancies.
The Local Central Lab Model
With globalization of trials comes the difficulties of sample logistics. Enter the central laboratory model.
Genotyping: Under the Microscope
Dr. Steve Dodsworth, director of molecular genetic services for Tepnel Research Products & Services, assesses that with molecular insight comes the opportunity to counter disease development and progression.
Russia Grows its CRO Market
Since 1993, investments from big pharma have helped develop a solid infrastructure favorable to CROs.
Business and People Update April 2008
A look at the latest industry news
CDER Gains Permanent Chief
Janet Woodcock is welcomed back as the director of the Center for Drug Evaluation and Research (CDER).
Europe's Thirst for Trial Information
New regulations prompt the EU to request more info from sponsors on clinical trial applications.
